ASBP

Aspire Biopharma Holdings, Inc.

NasdaqCMUSDEQUITY DELAYED

8.16

▲ 0.34 (4.35%)

MARKET · —

Price

Open

7.82

Prev close

7.82

Day high

8.20

Day low

7.90

Volume

30.36K

Market cap

—

P/E (TTM)

—

52W range

0.11 – 23.80

Trailing performance

Price return · vs SPY

Returnvs SPY

+1.53% +2.9%

+10.54% +6.8%

+42.58% +39.5%

+457.34% +446.3%

YTD

+50.95% +38.7%

-61.68% -81.7%

-98.19% -172.4%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

7.66

+6.58% from price

SMA 20

7.30

+9.22% from price

SMA 50

6.66

+19.69% from price

SMA 100

4.73

+72.35% from price

SMA 200

3.89

+105.08% from price

EMA 12

7.60

+7.40% from price

EMA 26

7.22

+12.97% from price

EMA 50

6.57

+24.23% from price

RSI (14)

59.5

Neutral

MACD (12,26,9)

0.37

Hist 0.02

ATR (14)

0.59

7.37% of price

Realised vol 30D

118.3%

Annualised

Bollinger upper

8.42

20, 2σ

Bollinger lower

6.17

20, 2σ

50 / 200 cross

Golden

6.66 vs 3.89

Trend bias

Above 200

+105.08%

Risk profile

Daily returns · 1Y window

Beta vs SPY

5.19

More volatile than market

Correlation to SPY

0.02

Largely independent

Realised vol 30D

118.3%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-99.3%

Peak to trough

Max drawdown 5Y

-100.0%

Peak to trough

ATR 14

0.59

7.37% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 8.16

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

ASBP · links out to the publisher

Sidoti Events, LLC's August Micro-Cap Virtual Conference ACCESS Newswire · 4d ago Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th ACCESS Newswire · 9d ago EXCLUSIVE: Aspire Biopharma Buys Its Way Into Global Auto Market With $30 Million DCS Deal Benzinga · 12d ago Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue ACCESS Newswire · 12d ago Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma's BUZZ BOMB(TM) ACCESS Newswire · 33d ago OTC Markets Life Sciences Investor Forum: Stephen Quesenberry, General Counsel and Director of Product Development, of Aspire Biopharma with Zacks SCR’s David Bautz, PhD Zacks Small Cap Research · 43d ago Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing GlobeNewswire · 57d ago Aspire Biopharma's BUZZ BOMB(TM) Launches on Amazon, Introducing Next-Generation Caffeine Stick Packs ACCESS Newswire · 59d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.